September 1, 2000Cardiovascular ResearchOpen Access

Differential antiplatelet efficacy for various GPIIb/IIIa antagonists Role of plasma calcium levels

View Full Paper

Ask AI

Bookmark

Why the study?

Does the method of blood collection and resulting plasma calcium levels affect the antiplatelet efficacy of different classes of GPIIb/IIIa antagonists in human platelets?

Population

Activated human platelets from blood treated with citrate or heparin

Comparison

Class I and Class II GPIIb/IIIa antagonists vs Different calcium concentrations

Design

Preclinical

Authors

SMShaker A. MousaUniversity of North Carolina at Chapel Hill

Discussion

Member takes

Implication

In vitro potency of Class II GPIIb/IIIa antagonists may vary with anticoagulant; hypothesis-generating for calcium effects on human platelet testing.

Structured PICO

Does the method of blood collection and resulting plasma calcium levels affect the antiplatelet efficacy of different classes of GPIIb/IIIa antagonists in human platelets?

Population

Activated human platelets from blood treated with citrate or heparin

Intervention

Class I (Roxifiban, Abciximab) and Class II (Orbofiban, Integrilin) GPIIb/IIIa antagonists

Comparator

Different calcium concentrations (citrate vs. heparin or PPACK)

Outcome

Antiplatelet efficacy (IC50s) and platelet binding kineticssurrogate

The antiplatelet efficacy of class II, but not class I, GPIIb/IIIa antagonists is significantly impacted by plasma calcium levels and the method of blood collection.

Cite This Study

Shaker A. Mousa (2000) studied this question.

synapsesocial.com/papers/6a6fa161ac440176ef284c00 https://doi.org/10.1016/s0008-6363(00)00150-4

View Full Paper

Ask AI

Bookmark

September 1, 2000Cardiovascular ResearchOpen Access

Differential antiplatelet efficacy for various GPIIb/IIIa antagonists Role of plasma calcium levels

View Full Paper

Ask AI

Bookmark

Why the study?

Does the method of blood collection and resulting plasma calcium levels affect the antiplatelet efficacy of different classes of GPIIb/IIIa antagonists in human platelets?

Population

Activated human platelets from blood treated with citrate or heparin

Comparison

Class I and Class II GPIIb/IIIa antagonists vs Different calcium concentrations

Design

Preclinical

Authors

SMShaker A. MousaUniversity of North Carolina at Chapel Hill

Discussion

Member takes

Implication

In vitro potency of Class II GPIIb/IIIa antagonists may vary with anticoagulant; hypothesis-generating for calcium effects on human platelet testing.

Structured PICO

Does the method of blood collection and resulting plasma calcium levels affect the antiplatelet efficacy of different classes of GPIIb/IIIa antagonists in human platelets?

Population

Activated human platelets from blood treated with citrate or heparin

Intervention

Class I (Roxifiban, Abciximab) and Class II (Orbofiban, Integrilin) GPIIb/IIIa antagonists

Comparator

Different calcium concentrations (citrate vs. heparin or PPACK)

Outcome

Antiplatelet efficacy (IC50s) and platelet binding kineticssurrogate

The antiplatelet efficacy of class II, but not class I, GPIIb/IIIa antagonists is significantly impacted by plasma calcium levels and the method of blood collection.

Cite This Study

Shaker A. Mousa (2000) studied this question.

synapsesocial.com/papers/6a6fa161ac440176ef284c00 https://doi.org/10.1016/s0008-6363(00)00150-4

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark